渤健公司 BIIB 深 滬
等待開盤 09-27 09:30:00 美东时间
136.29
+0.620
+0.46%
華盛通- 最 高138.00
- 今 開136.79
- 成交量 88.62万股
- 最 低 135.84
- 昨 收 135.67
- 總市值 200.35亿
- 52周最高 194.13
- 市盈率 靜 12.18
- 換手率 0.60%
- 52周最低 110.035
- 委 比 -71.88%
- 總股本 1.47亿
- 歷史最高 468.55
- 量 比 0.63
- 振 幅 1.59%
- 歷史最低 61.605
- 每 手 1
- 風險率 19.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Jefferies Initiates Coverage On Biogen with Buy Rating, Announces Price Target of $190
Jefferies analyst Andrew Tsai initiates coverage on Biogen (NASDAQ: BIIB) with a Buy rating and announces Price Target of $190.
09-25 19:05
美股盘后 | Iris Energy Limited涨3.31%，艾涛巴西联合银行涨2.88%
Iris Energy Limited涨3.31%；艾涛巴西联合银行涨2.88%；渤健公司涨2.25%
09-25 06:11
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
Eisai and Biogen announce that LEQEMBI, a humanized anti-soluble aggregated amyloid-beta monoclonal antibody, has been approved by the Australian TGA for mild cognitive impairment or mild dementia due to Alzheimer's disease in adults who are either ApoEε4 non-carriers or heterozygous carriers. Approval is based on Phase 3 Clarity AD trial data, showing a 33% reduction in clinical decline compared to placebo. Eisai leads global development, with b...
09-24 11:30
快讯 | 百健公司 - 完全回应函未提及高剂量方案临床数据存在缺陷
Biogen Inc - Crl Did Not Cite Deficiencies in Clinical Data for High Dose Regim...
09-24 04:30
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
Biogen received a Complete Response Letter from the FDA regarding its high-dose nusinersen sNDA for SMA treatment. The letter requested updated technical information but did not cite clinical data deficiencies. Biogen plans to resubmit the application promptly. The high-dose regimen is approved in Japan and under review by EMA and other global regulators.
09-23 20:30
徘徊生死线上的Biotech，首席财务官辞职
近日，Sangamo Therapeutics的首席财务官Prathyusha Duraibabu通知公司，她决定辞去CFO职务，辞职将于2025年10月1日生...
09-23 12:03
渐冻症药物支付难，渤健丁伟波：商保创新药目录或成新解法，如何落地是关键
本文来源：时代财经 作者：张羽岐 渤健（Biogen）亚太区总裁丁伟波。图片来源：受访者提供 罕见病的有效治疗，不仅需要推动诊断前置，更需要通过多方共付机...
09-22 11:41
每日全球并购：罗氏将收购生物制药公司89bio | 百健宣布收购Alcyone Therapeutics（9/19）
登录新浪财经APP 搜索【信披】查看更多考评等级 -每日资讯- 1、甘肃国投拟收购兰石重装 甘肃省国资委拟将其持有的兰石集团90...
09-19 20:27
